Rezultati pretraživanja
  1. prije 10 sati

    Forest from the trees is that is taking advantage of multiple avenues to optimize combination therapies in the MAPK/RAS pathway, currently one of the hottest spaces in targeted oncology.

    Prikaži ovu nit
  2. prije 10 sati

    Revolution Medicines is an interesting co - they have a 50/50 split with Sanofi on lead asset, along with covering essentially all costs of co-development w/ AMG 510. SHP2 is a tough target (as was KRAS) but many recent publications on rationale of co-targeting both

    Prikaži ovu nit
  3. Revolution Medicines, Inc. (IPO) is now on RetailRoadshow.

  4. 4. velj

    Good we have two solid bio names with filing yesterday and setting up for next week. These two will go with my , cohort of bios...

  5. 4. velj
    Odgovor korisnicima i sljedećem broju korisnika:

    and up next Has market tired if and ?

  6. 4. velj

    : Another big next Wed. 2/12. Revolution Medicines. Expanding pool of patients who can benefit from targeted therapy. If IPO last week is any indication, this one will outperform. S-1 -->

  7. 3. velj

    New Expected IPOs: NexPoint Real Estate Finance, Inc. Professional Holding Corp. Revolution Medicines, Inc. More info about :

  8. 3. velj
  9. 3. velj
  10. 3. velj

    Revolution Medicines, Inc. , a clinical-stage precision oncology company, has set terms for $150 mil IPO, offering 10,000,000 shares at a price range of $14.00 to $16.00 per share

  11. 3. velj
  12. 3. velj

    Revolution Medicines has launched its IPO. Terms are as follows: Debut date 2/13 10mm shares Price Range: $14.00-$16.00

  13. 21. sij
  14. 21. sij

    For , unfortunately SHP-2 has major tox and the way they are trying to get around it is thru intermittent dosing. This also will be difficult to make the pitch on combo-ing the agent. A few stable a response in dose escalation. Will be all about KRAS asset that's early.

    Prikaži ovu nit
  15. 21. sij

    ICYMI, Revolution Medicines filed for a $100M late last week. Lead drug is in Phase 1 testing under partnership with Sanofi...

  16. 20. sij
  17. 20. sij
  18. 20. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.